Agios Pharmaceuticals Appoints David Schenkein, M.D., as CEO and Duncan Higgons as COO

“Agios is a special company. In less than a year it has emerged as the recognized leader in the field of cancer metabolism and also presents a unique opportunity to build one of the next truly meaningful biotech companies,” said Mr. Higgons, Agios Chief Operating Officer. “I’m excited to work with David to build this important company. Our skills and background are highly complementary and will allow us to develop and execute a company strategy that fully explores the potential of cancer metabolism. Importantly, we are both focused on maintaining and fostering a passionate, science driven culture that sees no barriers.”

Mr. Higgons brings to Agios a proven commitment to successful company building, including leadership roles at Lilly, Alkermes, Transform, and most recently, Archemix. His leadership experience has spanned multiple business functions including business development, human resources, corporate development, legal affairs and financial operations. Over the past ten years, Mr. Higgons has been instrumental in architecting and executing company partnerships and M&A in multiple companies and settings with demonstrated value of many hundreds of millions of dollars. Mr. Higgons will be broadly responsible for leading the overall corporate development strategy of the company with direct oversight of business related functions

Prior to joining Agios, Mr. Higgons served as Chief Operating Officer, President and interim Chief Executive Officer at Archemix where he was promoted to that position after serving as Archemix’s Executive Vice President, leading the company’s business operations. Formerly, Mr. Higgons served as Chief Commercial Officer for TransForm Pharmaceuticals, a privately held biotechnology company that was acquired by Johnson & Johnson and as Senior Vice President, Business Development and Marketing for Alkermes, Inc. Additionally Mr. Higgons served in senior management positions at Eli Lilly and Co. and Baxter International, Inc.

“We have spent the last year building one of the leading new companies in the oncology space. Key to this has been outstanding science, great culture and focused execution,” said Kevin Starr, interim Chief Executive Officer, Agios Pharmaceuticals and Partner, Third Rock Ventures. “David and Duncan represent a continuation and enhancement of that vision. Needless to say, we are excited to be able to bring in such extraordinary and unique leadership that is ideally suited to lead and grow the Agios vision.”

1 2 3 4

Share